<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03255408</url>
  </required_header>
  <id_info>
    <org_study_id>REB13-0880</org_study_id>
    <nct_id>NCT03255408</nct_id>
  </id_info>
  <brief_title>Cerebral Blood Flow and Ventilatory Responses During Sleep in Normoxia and Intermittent Hypoxia</brief_title>
  <official_title>Role of Cerebral Blood Flow on Ventilatory Stability During Sleep in Normoxia and Intermittent Hypoxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective double blind, placebo-controlled, randomized cross-over trial to evaluate the
      effect of lowering cerebral blood flow on the ventilatory chemoreflexes (acute hypoxic and
      hypercapnic ventilatory responses).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will explore the relationship between changes in Cerebral Blood Flow (CBF)
      and ventilatory chemoreflexes i.e. Acute Ventilatory Response to Hypoxia (AHVR) and Acute
      Hypercapnic Ventilatory Response (HCVR) before, during and after sleep under normoxic
      conditions and sleep accompanied by isocapnic Intermittent Hypoxia (IH) among healthy human
      study participants.

      A pharmacological intervention will be utilized to manipulate the CBF in a randomized order.
      The study participants will also be randomly assigned the order to sleep either under
      normoxia or IH exposure. The experiments will be separated from one another with an interval
      of sufficient drug and IH exposure washout period. The venous blood samples and urinary
      samples will be collected for the vascular biomarkers.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 31, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in cerebral blood flow and ventilatory chemoreflexes</measure>
    <time_frame>~18 months (from the starting time of recruiting study participants)</time_frame>
    <description>The relationship between changes in cerebral blood flow (CBF) and ventilatory chemoreflexes (acute hypoxic and hypercapnic ventilatory responses) before and after sleeping under normoxia and intermittent hypoxia exposure among healthy human study participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cerebral blood flow responses and ventilatory chemoreflexes during sleep</measure>
    <time_frame>~18 months (from the starting time of recruiting study participants)</time_frame>
    <description>The relationship between cerebral blood flow (CBF) changes and ventilatory chemoreflexes (acute hypoxic and hypercapnic ventilatory responses) during sleep under normoxia and intermittent hypoxia exposure among healthy human study participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in reactive oxygen species and vascular biomarkers</measure>
    <time_frame>~24 months (from the starting time of recruiting study participants)</time_frame>
    <description>The changes in vascular biomarkers such as nitric oxide, reactive oxygen species and exosome analysis or urinary prostaglandins before and after sleep under normoxia and intermittent hypoxia exposure with cerebral blood flow changes.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Obstructive Sleep Apnea of Adult</condition>
  <condition>Hypoxia, Brain</condition>
  <condition>Sleep Apnea</condition>
  <condition>Sleep Disorder</condition>
  <condition>Stroke</condition>
  <condition>Blood Pressure</condition>
  <condition>Endothelial Dysfunction</condition>
  <condition>Oxidative Stress</condition>
  <arm_group>
    <arm_group_label>CBF Lowering and Normoxia Sleep</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study participants will take drug lowering Cerebral Blood Flow (CBF) and sleep under room air i.e. normoxia exposure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CBF Lowering and IH Sleep</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study participants will take drug lowering Cerebral Blood Flow (CBF) and sleep under Intermittent Hypoxia (IH) exposure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and Normoxia Sleep</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Study participants will take Placebo that has no effect on Cerebral Blood Flow (CBF) and sleep under room air i.e. normoxia exposure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and IH Sleep</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study participants will take Placebo that has no effect on Cerebral Blood Flow (CBF) and sleep under Intermittent Hypoxia (IH) exposure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug Lowering Cerebral Blood Flow (CBF) and Normoxia Sleep</intervention_name>
    <description>The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Normoxia Exposure</description>
    <arm_group_label>CBF Lowering and Normoxia Sleep</arm_group_label>
    <other_name>Cerebral Blood Flow changes and Normoxia Sleep</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug Lowering CBF and Intermittent Hypoxia Sleep</intervention_name>
    <description>The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Intermittent Hypoxia (IH) Exposure</description>
    <arm_group_label>CBF Lowering and IH Sleep</arm_group_label>
    <other_name>CBF changes and Intermittent Hypoxia Sleep</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo and Normoxia Sleep</intervention_name>
    <description>The study participants will take Placebo and sleep under Normoxia Exposure</description>
    <arm_group_label>Placebo and Normoxia Sleep</arm_group_label>
    <other_name>Cerebral Blood Flow (CBF) with Placebo in Normoxia Sleep</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo and Intermittent Hypoxia Sleep</intervention_name>
    <description>The study participants will take Placebo and sleep under Intermittent Hypoxia (IH) Exposure</description>
    <arm_group_label>Placebo and IH Sleep</arm_group_label>
    <other_name>CBF with Placebo in Intermittent Hypoxia Sleep</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults

          -  18 - 45 years of age

          -  Living in Calgary for the past one year

          -  Have no medical condition or should not be taking any blood pressure medications.

          -  The participant should not be lactose intolerant

        Exclusion Criteria:

          -  Cerebrovascular, cardio-respiratory, renal and metabolic diseases

          -  Bleeding disorders and upper gastrointestinal diseases e.g. peptic ulcer disease

          -  Pregnancy, obese and sleep-disordered breathing

          -  Drug allergies to non-steroidal anti-inflammatories

          -  Currently smoking
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2017</study_first_submitted>
  <study_first_submitted_qc>August 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2017</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Calgary</investigator_affiliation>
    <investigator_full_name>Marc Poulin</investigator_full_name>
    <investigator_title>PhD, DPhil, Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Hypoxia, Brain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

